Downes, M, Algaba, F, Allory, Y, Amin, M, Cheng, L, Desai, S, Eckstein, M, Hartmann, A, Lajkosz, K, Lopez-Beltran, A, Oxley, J, Paner, G, Samaratunga, H, Shen, S, van Montfoort, M, Warrick, J, Williamson, S, Wobker, S, van der Kwast, T. Inter-observer Reproducibility of a Three-Tier Grading System of Papillary Non- Muscle Invasive Urothelial Carcinoma: An International Uropathology Study. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).

Vilaseca, A, Jayram, G, Raventos, C, Shore, ND, Zainfeld, D, Kang, TW, Ku, JH, Meeks, J, Faba, OR, Roghmann, F, Daneshmand, S, Beeharry, N, Cost, CR, Kalota, A, Lauring, J, Peterson, MR, Quiroz, MQ, Stone, NL, Zhu, W, Gurrero-Ramos, F. First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations. EUROPEAN UROLOGY. 2024; 85DOI:. PMID:. IF:25.200(Q1/1D).

Henriquez, JDS, Krajewski, W, González-Padilla, D, Taborda, J, Andrzej, T, Aumatell, JL, Rodrigo, E, Moschini, M, Cano-Velasco, J, Gallioli, A, D Andrea, D, Pilcher, R, Afferi, L, Del Giudice, F, Albisinni, S, Soria, F, Laura, M, Szydelko, T, Burgos, JB, Gonzalez, AS, Medina, AA, Dos Santos, VG, Cidre, MNJ, Revilla, FJB. Is there a role for Bacillus Calmette-Guerin in very high-risk non-muscle invasive bladder carcinoma? Multicenter analysis of oncological outcomes and risk dynamics. EUROPEAN UROLOGY. 2024; 85DOI:. PMID:. IF:25.200(Q1/1D).

Gallioli, A, Uleri, A, Mertens, L, Tedde, A, Moschini, M, Del Giudie, F, Soria, F, Laukhtina, E, Daniel, SJ, Krajewski, W, D'Andrea, D, Mari, A, Marcq, G, Mori, K, Teoh, J, Afferi, L, Basile, G, Territo, A, Sanguedolce, F, Breda, A, Pradere, B. Oncologic outcomes of endoscopic management of upper tract urothelial carcinoma: A systematic review and pooled analysis from the EAU-YAU Urothelial Working Group. EUROPEAN UROLOGY. 2024; 85DOI:. PMID:. IF:25.200(Q1/1D).